http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-T63843-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6952371af45c4c8a1214fcb1507d6887 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D335-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D335-06 |
| filingDate | 1992-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b36dea9529c4d502f9295bb374b2c03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6da73bde36ab69842f74b27d71b8f866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ac9698ed53af36305ad0a8200e1f0bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_342c6b23c9a84ad90c87cab8ce83862a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ff20c23c1c3b7e79d3e802251369095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a444f8439cdfe5c7b1349ea34cd94ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2403bd6c0a0f845f215d343e285ce804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88971018bbc81c397e195e3478412c89 |
| publicationDate | 1993-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-T63843-A |
| titleOfInvention | Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds |
| abstract | The invention relates to novel compounds of general formula (I), wherein R1 stands for -CN, -COOH, -CSOH, -COSH, -CONH2, -CSNH2, -NHCHO, -COOCH3, -CSOCH3, -COSCH3, -COOCH2CH3, -CSOCH2CH3, -COSCH2CH3, -NHCOCH3, -NHCSCH3, -CS-NH-CONH2, -CO-NH-CONH2, -CO-NH-CSNH2, -CS-NH-CSNH2, -C(NH2)=C(CN)2, -CH(CN)2, -CH(CN)-COOH, -CH(CN)-CONH2, -CH(CN)-CSNH2, -CH(CN)CSNH-C1-4 alkyl, -NO2 or -NO group; X means =O, =S or =NH group; Y means -O-, -S- or -NH- group; R2 and R4, independently from each other, represent hydrogen atom, -OH, -SH, -NH2, -CF3, C1-4 alkoxy or C1-4 alkylthio group; R3 stands for -OH, -SH, -NH2, -CF3, -NO, -O-SO2-V<0>, -O-CO-V<0>, -O-CS-V<0>, -S-CO-V<0>, -NH-CO-V<0> or -CH=CH-V<0> group, wherein V<0> stands for 3,4,5-tri-V<1>-phenyl group; and the V<1> substituents, independently from each other, mean hydrogen or halogen atom or -OH, -SH, -NH2, -CF3, C1-4 alkoxy, C1-4 alkylthio or C1-4 alkylamino group; or V<1> bound in the 3- or 4-position may be -COOH, -CSOH, -COSH, -CONH2, C1-4 dialkylamino, pyridyl, -CH2-2-pyridyl, -O-CH2-O- or -N(CH2-V<2>)-CH2-V<3> group, wherein V<2> and V<3>, independently from each other, stand for -OH, -SH, -NH2, -CF3, C1-4 alkyl, C1-4 alkoxy or C1-4 alkylthio group; or V<2> and V<3> together stand for -NH-CH2-NH- or -N(CH3)-CH2-N(CH3)- group; R5 represents hydrogen, C1-4 alkyl, C1-4 alkoxy group or halogen; and the double bond belonging to the skeletal atom substituted by R1 can also be saturated when R3 is a substituent containing the -3,4,5-tri-V<1>-phenyl moiety, as well as physiologically acceptable salts and complexes of these compounds. The invention furthermore relates to pharmaceutical compositions containing the above compounds as well as processes for the preparation of the above compounds and compositions. The compounds of formula (I) are prepared by condensing a phenol or benzaldehyde derivative with a bifunctional carboxylic acid derivative. The compounds of formula (I) show a tumour-inhibititing action: they inhibit the activity of tyrosine kinase enzymes playing a role in the signal transfer mechanism, but do not practically influence the activity of insulin-receptor tyrosine kinase. |
| priorityDate | 1992-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.